🇺🇸 FDA
Patent

US 12134610

Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

granted A61KA61K47/545A61K47/65

Quick answer

US patent 12134610 (Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof) held by CRINETICS PHARMACEUTICALS, INC. expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRINETICS PHARMACEUTICALS, INC.
Grant date
Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K47/545, A61K47/65, A61K51/0455, A61K51/0497